Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period - Deitcher, SR; Kessler, CM; Merli, G (Clin Appl Thromb He-most, 2006)